Physician profile
Alejandro Fuentes
NPI 1619940475
$2,087.78
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,249 · 2020: $438 · 2021: $151 · 2022: $125 · 2024: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $385.70 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $312.79 | 2019-2020 | |
| Novo Nordisk INC | $289.70 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $186.64 | 2019-2021 | |
| Romark Laboratories, Lc | $182.11 | 2019-2020 | |
| Vifor Pharma, INC. | $125.00 | 2024 | Veltassa |
| Optinose US, INC. | $124.99 | 2022 | |
| Allergan, INC. | $78.63 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.46 | 2019-2020 | |
| Glaxosmithkline, LLC. | $50.95 | 2019 | |
| Amarin Pharma, INC. | $44.50 | 2019-2020 | |
| Lilly USA, LLC | $39.84 | 2019 | |
| Merck Sharp & Dohme LLC | $38.18 | 2019 | |
| Abbvie INC. | $37.95 | 2021 | |
| Mannkind Corporation | $25.94 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $17.09 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.80 | 2019 | |
| Pfizer INC. | $15.43 | 2019 | |
| Amgen INC. | $13.89 | 2021 | |
| Genentech USA, INC. | $13.83 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.10 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Fuentes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.